KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 63 filers reported holding KINNATE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $780,161 | -71.5% | 557,258 | -38.2% | 0.00% | -100.0% |
| Q2 2023 | $2,733,793 | +189.9% | 902,242 | +1043.7% | 0.00% | 0.0% |
| Q3 2022 | $943,000 | +512.3% | 78,889 | +476.5% | 0.00% | – |
| Q1 2022 | $154,000 | -94.4% | 13,683 | -88.5% | 0.00% | -100.0% |
| Q3 2021 | $2,733,000 | -23.5% | 118,734 | +32.2% | 0.00% | -33.3% |
| Q4 2020 | $3,572,000 | – | 89,796 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,525,957 | $4,936,340 | 7.88% |
| Foresite Capital Management IV, LLC | 9,671,643 | $13,540,300 | 7.52% |
| Vida Ventures Advisors, LLC | 2,207,772 | $3,090,881 | 4.78% |
| Lynx1 Capital Management LP | 1,997,006 | $2,795,808 | 1.85% |
| Nextech Invest Ltd. | 2,329,480 | $3,261,272 | 0.99% |
| Orbimed Advisors | 8,009,729 | $11,213,621 | 0.24% |
| Novo Holdings A/S | 815,707 | $1,141,990 | 0.08% |
| DAFNA Capital Management LLC | 105,179 | $147,251 | 0.05% |
| GSA CAPITAL PARTNERS LLP | 374,291 | $524 | 0.04% |
| Rock Springs Capital Management LP | 405,811 | $568,135 | 0.02% |